An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

Clinical trial NCT05492877 · COMPLETED

Trial details

NCT number: NCT05492877
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Obstructive Pulmonary Disease (COPD)

Start date: 2022-11-14
Primary completion: 2024-08-12
Enrollment: 381

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.